Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study
2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor
Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication
Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy
Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation
Canine hepacivirus and idiopathic hepatitis in dogs from a Dutch cohort
Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline
A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation
Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss
APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)
HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers
Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population
The validity of serum markers for fibrosis staging in chronic hepatitis B and C
Association between chronic hepatitis C virus infection and low muscle mass in US adults
Interferon–ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients
Telomeric 1p36.3 deletion and Ki-67 expression in B-Non-Hodgkin's Lymphoma patients associated with chronic hepatitis C virus infection
CUFA algorithm: assessment of liver fibrosis using routine laboratory data
Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue
Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue